Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/28—Compounds containing heavy metals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention relates to pharmaceutical preparations, particularly preparations for therapeutic delivery of carbon monoxide to humans and other mammals, to methods of delivery of therapeutic agents and to kits for this purpose.
• nitric oxide (NO) and carbon monoxide (CO) gases have been known for some time (3) .
• the L-arginine/NO synthase pathway present in the vascular endothelium plays a fundamental role in the control of vessel relaxation and arterial blood pressure in mammals (4) .
• Increased generation of carbon monoxide (CO) following activation of the he e oxygenase-1 enzyme in the vascular tissue also results in suppression of acute hypertension in vivo (6) and prevention of vasoconstriction ex vivo (7) .
• CO-RMs CO- releasing molecules
• vascular relaxation by NO and CO appears to involve an increase in intracellular cyclic 3 ' , 5' -guanosine monophosphate (cGMP) levels through activation of a soluble heme-dependent guanylate cyclase (sGC) (3; 6; 7) .
• cGMP cyclic 3 ' , 5' -guanosine monophosphate
• sGC soluble heme-dependent guanylate cyclase
• CO is a poor stimulator of sGC in in vi tro studies when compared to NO; the enzymatic activity of purified guanylate cyclase is increased 130- fold and 4.4-fold by its interaction with NO and CO, respectively (8) .
• YC-1 benzyl-indazole derivative 3- (5' -hydroxymethyl-2 ' - furyl) -1-benzyl-indazole (YC-1) .
• the mechanism underlying YC-1 action may be the stabilization of guanylate cyclase in its active conformation. It has also been suggested that YC-1 may stimulate production of guanylate cyclase.
• WO02/092075 published 21 November 2002 and originating from work of the present inventors, discloses various metal carbonyl compounds that can be used in the delivery of carbon monoxide to body cells and tissue. Some of the metal carbonyl compounds disclosed therein typically included a ligand other than CO and can be employed in the present invention. There is a statement that YC-1 may be used as a ligand.
• An object of the present invention is to provide method of achieving improved therapeutic effects by delivery of carbon monoxide to the human or other mammal body.
• the present inventors have found that metal carbonyl compounds can be used in combination with a guanylate cyclase stimulant or stabilizer so as to provide an improved physiological effect .
• the present invention provides a pharmaceutical preparation, comprising a metal carbonyl compound or pharmaceutically acceptable salt thereof, a guanylate cyclase stimulant or stabilizer and at least one pharmaceutically acceptable carrier.
• the metal carbonyl makes available CO suitable for physiological effect, for delivery of carbon monoxide to a physiological target.
• the preparation may contain the metal carbonyl and guanylate cyclase stimulant/stabilizer in a single composition, or the two components may be formulated separately for simultaneous or sequential administration.
• the present invention provides a method of a therapeutic agent to a mammal comprising the step of administering a pharmaceutical preparation according to the first aspect .
• the present invention provides a method of introducing therapeutic agent to a mammal, comprising: a) administering a metal carbonyl; and b) administering a guanylate cyclase stimulant or stabiliser.
• the metal carbonyl and guanylate cyclase stimulant/stabilizer may be administered simultaneously either in a single composition or in two separate compositions.
• the metal carbonyl and stimulant/stabilizer may be administered sequentially.
• the stabilizer/stimulant is administered first followed by the metal carbonyl but this order may be reversed.
• the invention provides a kit comprising a) a metal carbonyl compound and b) a guanylate cyclase stimulant/stabilizer.
• the two components may be for administration simultaneously or sequentially.
• the invention is primarily here discussed as involving the delivery of carbon monoxide to a physiological target wherein the metal carbonyl makes CO available for physiological effect, it is not excluded that a different mechanism is involved, such as that the metal carbonyl acts directly without release of CO.
• the various aspects of this invention are useful for treating a variety of body tissues in a living mammal.
• isolated organs e.g. extracorporeal organs or in situ organs isolated from the blood supply, can be treated.
• the organ may be, for example, a circulatory organ, respiratory organ, urinary organ, digestive organ, reproductive organ, neurological organ, muscle or skin flap or an artificial organ containing viable cells.
• the organ may be a heart, lung, kidney or liver.
• the body tissue which is treatable are not limited and may be any human or mammal body tissue whether extracorporeal or in situ in the animal body.
• the various aspects of the present invention are used to provide a physiological effect, e.g. for stimulating neurotransmission or vasodilation, or for treatment of any of hypertension, such as acute, pulmonary and chronic hypertension, radiation damage, endotoxic shock, inflammation, inflammatory-related diseases such as asthma and rheumatoid arthritis, hyperoxia-induced injury, apoptosis, cancer, transplant rejection, arteriosclerosis, post-ischemic organ damage, yocardial infarction, angina, haemorrhagic shock, sepsis, penile erectile dysfunction, adult respiratory distress syndrome and inhibition of platelet aggregation.
• hypertension such as acute, pulmonary and chronic hypertension, radiation damage, endotoxic shock, inflammation, inflammatory-related diseases such as asthma and rheumatoid arthritis, hyperoxia-induced injury, apoptos
• the various aspects can also be used for perfusion, of a viable mammalian organ extracorporeally, e.g. during storage and/or transport of an organ for transplant surgery or treatment of an organ which is in the body but is temporarily isolated from the bloodstream, e.g. during surgery.
• the metal carbonyl is in dissolved form, preferably in an aqueous solution.
• the metal carbonyl makes CO available by at least one of the following means:
• the metal carbonyl on irradiation the metal carbonyl releases CO.
• the most preferred metal carbonyls are water soluble metal carbonyls.
• Certain metal carbonyl compounds are capable of releasing CO on contact with a suitable solvent. When the metal carbonyl component is to be administered in liquid form, this solvent may form a part of the component. Thus, the pharmaceutical preparation contains CO derived from the metal carbonyl in dissolved form. The conditions under which the carbonyl compound is dissolved in the solvent during preparation of the metal carbonyl component may be controlled such that the CO thus released is retained in solution. This may be facilitated where an equilibrium exists between the dissociated components and the undissociated carbonyl.
• the dissociated components of the parent carbonyl may themselves be metal carbonyl complexes capable of releasing further CO.
• the metal carbonyl component may not itself contain dissolved CO, but may be prepared such as to release CO on contact with a suitable solvent or medium.
• the composition may contain a metal carbonyl compound capable of releasing CO on contact with water, e.g. on contact with an aqueous physiological fluid, such as blood or lymph.
• the metal carbonyl compound may also release CO on contact with perfluorocarbon type blood substitute fluids or on contact with cardioplegic fluid.
• the pharmaceutical composition may be intended to be dissolved in water prior to administration.
• metal carbonyl components may be prepared in solution or in solid form, such as in tablet form. If they are in solution form, they will typically be prepared in a solvent which does not support dissociation of the metal carbonyl compound, such that release of CO takes place only on contact with the appropriate substance .
• release of CO from the carbonyl can be stimulated by reaction with a ligand in solution which for example replaces one of the ligands of the complex leading to loss of CO from the complex.
• the ligand may be one containing sulphur or nitrogen.
• the metal carbonyl component may contain a metal carbonyl compound which releases CO on contact with a tissue, organ or cell. It is known that certain metal carbonyl compounds do not release CO to solution but are nevertheless capable of releasing CO to physiological cellular materials or tissues, such as vascular endothelium. For example, [Fe (SPh) 2 (2 , 2 ' - bipyridine) (CO) 2 ] does not release CO to myoglobin in solution, but is nevertheless capable of promoting dilatation of pre-contracted aortic rings.. Without wishing to be limited by any particular theory, it is thought that CO may be released from such compounds as a result of an oxidation-reduction reaction, mediated by cellular components such as cytochromes .
• the invention is not limited to a redox reaction as a mechanism for CO release, since loss of at least a first CO molecule from the complex may occur without redox.
• the metal carbonyl component may contain a metal carbonyl compound which releases CO on irradiation.
• the compound may be irradiated prior to administration, for example to produce a solution of dissolved CO, or may be irradiated in si tu after administration.
• compositions may be used to provide controlled, localised release of CO.
• a pharmaceutical composition of this type may be administered during surgery, and CO released specifically at a site in need thereof, e.g. to induce vasodilation, by localised irradiation by means of a laser or other radiant energy source, such as UV rays.
• the metal carbonyl components of the present invention release CO such as to make it available to a therapeutic target in dissolved form.
• the metal carbonyl compound comprises a complex of a transition metal, preferably a transition metal from group 6 to 10 (in this specification the groups of the periodic table are numbered according to the ITJPAC system from 1 to 18) .
• the number of carbonyl ligands is not limited, provided at least one carbonyl ligand is present.
• the preferred metals are transition metals of lower molecular weight, in particular Fe, Ru, Mn, Co, Ni, Mo and Rh. Two other metals which may be used are Pd and Pt.
• the metal is typically in a low oxidation state, i.e.
• the oxidation states are typically not higher than Fe 11 , Ru 11 , Mn 1 , Co 11 preferably Co 1 , Rh 111 preferably Rh 1 , Ni 11 , Mo 11 .
• the metal is preferably not a radionuclide.
• Fe is one particularly suitable metal, since Fe is present in quantity in mammals.
• the metal carbonyl compounds may be regarded as complexes, because they comprise CO groups coordinated to a metal centre .
• the metal may be bonded to other groups by other than coordination bonds, e.g. by ionic or covalent bonds .
• groups other than CO which form part of the metal carbonyl compound need not strictly be "ligands" in the sense of being coordinated to a metal centre via a lone electron pair, but will be referred to herein as "ligands" for ease of reference.
• the ligands to the metal may all be carbonyl ligands, as e.g. in [Mn 2 (CO) ⁇ 0 ].
• the carbonyl compound may comprise at least one modulatory ligand.
• a ligand which is not CO, but which modulates a particular property of the complex such as the tendency to release CO, solubility, hydrophobicity, stability, electrochemical potential, etc.
• suitable choices of ligand may be made in order to modulate the behaviour of the compound. For example it may be desirable to modulate the solubility of the compound in organic and/or aqueous solvents, its ability to cross cell membranes, its rate of release of CO on contact with a particular solvent or cell type, or on irradiation, etc.
• Such ligands are typically neutral or anionic ligands, such as halide, or derived from Lewis bases and having N, P, O, S or C as the coordinating atom(s) .
• Preferred coordinating atoms are N, 0 and S.
• Examples include, but are not limited to, sul oxides such as dimethylsulfoxide, natural and synthetic amino acids and their salts for example, glycine, cysteine, and proline, amines such as N ⁇ t 3 and H 2 NCH 2 CH 2 NH 2 , aromatic bases and their analogues, for example, bi-2, 2 ' -pyridyl, indole, pyrimidine and cytidine, pyrroles such as biliverdin and bilirubin, thiols and thiolates such as EtSH and PhSH, chloride, bromide and iodide, carboxylates such as formate, acetate, and oxalate, ethers such as Et 2 0 and tetrahydrofuran, alcohols such as EtOH, and nitriles such as MeCN.
• sul oxides such as dimethylsulfoxide
• natural and synthetic amino acids and their salts for example, glycine, cyst
• coordinating ligands such as amino acids, which render the carbonyl complex stable in aqueous solution.
• Other possible ligands are conjugated carbon groups, such as dienes.
• One class of ligands which can provide metal carbonyl compounds of use in this invention is cyclopentadienyl (C 5 H 5 ) and substituted cyclopentadienyl.
• the substituent group in substituted cyclopentadienyl may be for example an alkanol, an ether or an ester, e.g.
• n is 1 to 4, particularly -CH 2 OH, -(CH 2 ) n OR where n is 1 to 4 and R is hydrocarbon preferably alkyl of 1 to 4 carbon atoms and -(CH 2 ) n OOCR where n is 1 to 4 and R is hydrocarbon preferably alkyl of 1 to 4 carbon atoms .
• the preferred metal in such a cyclopentadienyl or substituted cyclopentadienyl carbonyl complex is Fe .
• the cyclopentadienyl carbonyl complex is cationic, being associated with an anion such as chloride.
• compositions of the present invention may be tailored as required by appropriate choice of metal centres and number and type of associated ligands in the metal carbonyl compound.
• the metal carbonyl compound may further comprise a targeting moiety, to facilitate release of CO at an appropriate site.
• the targeting moiety is typically capable of binding a receptor on a particular target cell surface, in order to promote release of CO at the required site.
• the targeting moiety may be a part of a modulating ligand capable of binding to a receptor found on the surface of the target cells, or may be derived from another molecule, such as an antibody directed against a particular receptor, joined to the complex by a suitable linker.
• the present invention also includes as the metal carbonyl component a compound of the formula M(CO) x A y where x is at least one, y is at least one, M is a metal, A is an atom or group bonded to M by an ionic, covalent or coordination bond but is not CO, and, in the case where y>l, each A may be the same or different, or a pharmaceutically acceptable salt of such a compound.
• M is a transition metal, particularly of groups 6 to 10
• A may be selected from neutral or anionic ligands, such as halide, or derived from Lewis bases and having N, P, O, S or C as the coordinating atom(s) .
• Mono-, bi- or polydentate ligands may be used.
• the molecular weight of this compound is preferably less than 1000, e.g. not more than 822.
• Some CO-releasing carbonyls and their release properties are given in Figs. 3A-3F.
• the carbonyl complex should be pharmaceutically acceptable, in particular non-toxic or of acceptable toxicity at the dosage levels envisaged.
• the metal carbonyl component may be a compound of the formula
• M(CO) x A y B z where M is Fe, Co or Ru, x is at least one, y is at least one, z is zero or at least one, each A is a ligand other than CO and is monodentate or polydentate with respect to M and is selected from the amino acids alanine arginine asparagine aspartic acid cysteine glutamic acid glutamine glycine histidine isoleucine leucine lysine methionine pheny1alanine proline serine threonine tryptophan tyrosine valine [0(CH 2 C00) 2 ] 2" and [NH(CH 2 COO) 2 ] 2" , and B is optional and is a ligand other than CO.
• x is preferably 3
• y is preferably 1 and z is preferably 1.
• amino acid here used includes the species obtained by loss of the acidic hydrogen, such as glycinato.
• B z represents one or more optional other ligands.
• ligands such as halides, e.g. chloride, bromide, iodide, and carboxylates, e.g. acetate may be used.
• M is selected from Fe, Ru and Co. These metals are preferably in low oxidation states, as described above.
• the guanylate cyclase stabilizer/stimulant compound may be any compound which stimulates production of guanylate cyclase or which stabilizes guanylate cyclase, in particular the active form of guanylate cyclase.
• a single compound can be used or a combination of compounds can be used either for simultaneous or sequential administration, i.e. the various aspects include/use at least one guanylate cyclase stimulant/stabilizer.
• Examples include 3- (5 ' -hydroxymethyl-2 ' -furyl) -1- benzyl-indazole (YC-1), 4 pyrimidinamine-5-cyclopropyl-2 - [1- [ (2-fluorophenyl) methyl] -lH-pyrazolo [3 , 4-b] yridin-3 - yl] (BAY 41-2272) , BAY 50-6038 (ortho-PAL) , BAY 51-9491 (meta PAL) , and BAY 50-8364 (para PAL) .
• the structures of ortho-, meta- and para- PAL are shown in Figure 2.
• the metal carbonyl component and/or guanylate cyclase stabilizer/stimulant component typically comprise a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere unduly with the efficacy of the active ingredient.
• the precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, subcutaneous, nasal, intramuscular, intraperitoneal, or suppository routes.
• Components/preparations for oral administration may be in tablet, capsule, powder or liquid form.
• a tablet may include a solid carrier such as gelatin or an adjuvant or a slow-release polymer.
• Liquid compositions/preparations generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. Pharmaceutically acceptable amounts of other solvents may also be included, in particular where they are required for dissolving the particular metal carbonyl compound contained in the composition.
• the composition may further comprise pharmaceutically acceptable additives such as suspending agents (e.g.
• sorbitol syrup cellulose derivatives or hydrogenated edible fats
• emulsifying agents e.g. lecithin or acacia
• non-aqueous vehicles e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
• preservatives e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid
• energy sources e.g. carbohydrates such as glucose, fats such as palmitate or amino acid
• the active ingredient will typically be in the form of a parenterally acceptable solution which is pyrogen-free and has suitable pH, isotonicity and stability.
• a parenterally acceptable solution which is pyrogen-free and has suitable pH, isotonicity and stability.
• Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. Delivery systems for needle-free injection are also known, and compositions for use with such systems may be prepared accordingly.
• Administration is preferably in a prophylactically effective amount or a therapeutically effective amount (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual .
• the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed) , 1980.
• the toxicity of the active ingredient, stimulant/stabilizer and/or the solvent must be considered.
• the balance between medical benefit and toxicity should be taken into account.
• the dosages and formulations will typically be determined so that the medical benefit provided outweighs any risks due to the toxicity of the constituents. Examples include St Thomas Hospital solutions, Euro-Collins solutions, University of Wisconsin solutions, Celsior solutions, Ringer Lactate solutions, Bretschneider solutions and perflurocarbons .
• the metal carbonyl compound and the stimulant/stabilizer can be formulated into a single composition that can be in any physical form. In this case, the components will be administered simultaneously. Alternatively, the components can be formulated into two compositions which can be administered simultaneously or sequentially.
• references to medical treatment are intended to include both human and veterinary treatment
• references to pharmaceutical compositions are accordingly intended to encompass compositions for use in human or veterinary treatment.
• Fig. 1A shows vasodilatory effects of CORM-3 alone and in combination with YC-1 obtained in Example 1;
• Fig. IB shows percentage relaxation obtained in Example 1;
• Fig. 2 shows structures of ortho-, meta- and para- PAL
• Figs . 3A to F show carbon monoxide releasing molecules
• Figs . 4A and 4B show absorbance data obtained in Example 2 ;
• Fig. 5 shows relaxation date of Example 3; Figs. 6A and 6B show data of Example 4A; Figs. 7A, 7B, 7C and 7D show data of Example 4B; Figs. 8A and 8B show data of Example 4C; and Fig. 9 shows data of Example 5.
• mM and ⁇ M signify concentrations (millimolar and micromolar respectively) .
• the method for the preparation of isolated aortic rings has been previously described (5; 7) .
• the thoracic aorta was isolated from Sprague-Dawley rats (350-450 g) and flushed with cold Krebs-Henseleit buffer (4°C, pH 7.4) containing (in M) : 118 NaCl, 4.7 KCl, 1.2 KH 2 P0 4 , 1.2 MgS0 4 .7H 2 0, 22 NaHC0 3 , 11 Glucose, 0.03 K + EDTA, 2.5 CaCl 2 and supplemented with 10 ⁇ M indomethacin.
• aorta was trimmed of adventitial tissue and ring sections ( ⁇ 3 mm length) were produced from the mid aortic segment.
• the rings were then mounted between two stainless steel hooks in 9-ml organ baths containing Krebs-Henseleit buffer which was maintained at 37 °C and continuously gassed with 95% 0 2 -5% C0 2 .
• One hook was attached to a Grass FT03 isometric force transducer whilst the other was anchored to a sledge for regulation of the resting tension of the aortic ring.
• the rings were initially equilibrated for 30 in under a resting tension of 2g which was previously determined to be optimal . Continuous recording of tension was made on a Grass 7D polygraph (Grass Instruments, Quincy, MA) in combination with a
• Figure 1A shows the typical plots of the vascular reactivity to phenylephrine and the vasodilatory effects of CORM-3 alone or in combination with YC-1 in this Example.
• three sequential additions of CORM-3 25 ⁇ M each
• the pre-contracted ring elicited vasorelaxation (see top plot) .
• the relaxation is expressed as a percentage of the maximal phenylephrine-mediated contraction, then we can calculate that CORM-3 produced a 10.3% relaxation after the first addition, 24.1% relaxation after the second addition and 38% after the third addition (Figure IB) .
• Example 2 and Example 3 are presented here as background, to illustrate the effects of CORM-3 in CO release and vasorelaxation.
• Myoglobin (Mb) in its reduced state displays a characteristic spectrum with a maximal absorption peak at 555 nm (see Fig. 4A, dotted line) .
• Mb carbon monoxide myoglobin
• Fig. 4A solid line
• MbCO displays a characteristic spectrum with two maximal absorption peaks at 540 and 576 nm, respectively. This method has been previously developed to monitor and determine the amount of CO released from CO-RMs (7) .
• Example 1 The preparation of isolated aortic rings and recording of tension was as in Example 1. Before each protocol was carried out, rings were contracted with a standard dose of KCl (100 mM) in order' to provide an internal reference and to control for variability in contractile responsiveness between tissues.
• the relaxation response to CORM-3 (25, 50 and 100 ⁇ M) in the presence and absence of YC-1 (1 ⁇ M final concentration, 30 min pre-incubation) was assessed in aortic rings precontracted with phenylephrine (1 ⁇ m) .
• CORM-3 was added to the aortic rings as three cumulative additions at 10 minute intervals and the percentage of relaxation produced was recorded after each addition.
• nitric oxide (NO) synthase pathway is involved in the vasorelaxing effects mediated by CORM-3
• a NO synthase inhibitor L-nitroarginine methyl esther or L-NAME, 10 ⁇ M was added to the aortic rings 30 min prior to CORM-3 addition.
• An additional set of experiments was performed in which the vascular endothelium was removed from the aortic tissue prior to CORM-3 addition.
• cyclic guanosine monophosphate As an index of direct guanylate cyclase activation by CORM-3, the levels of cyclic guanosine monophosphate (cGMP) were also measured in freeze-clamped aortic tissue extracts using a commercial ELISA kit (Amersham) as previously described (7) . The levels of cGMP in aortic tissue was measured 8 min after each of the three cumulative additions of CORM-3 (100 ⁇ M) and compared to the basal levels of cGMP (control, no treatment).
• Both inhibitors were very effective in attenuating the relaxation caused by CORM-3. For instance, the 37.5+5.3% relaxation elicited by CORM-3 following the first addition was reduced to 1.0+0.8% and 13.2+4.1% in the presence of ODQ and glibenclamide, respectively. During the first two additions of CORM-3, the inhibition of relaxation was more pronounced with ODQ.
• the data are represented as the mean+S.E.M. of 6 independent experiments for each group (*p ⁇ 0.05 vs. CORM- 3) .
• YC-1 sensitizes guanylate cyclase (sGC) to the effect of CO gas as previously reported by Friebe and colleagues (1; 2) .
• sGC guanylate cyclase
• YC-1 was added to the aortic ring preparation 30 min prior to the addition of CORM-3.
• the presence of YC-1 potentiated the relaxation elicited by CORM-3 (note: pre- treatment of YC-1 alone did not cause any significant change in vessel contractility) .
• YC-1 significantly amplified the reduction in contractility mediated by CORM-3 at all concentrations used.
• L-NAME The NO synthase inhibitor, L-NAME, was used to ascertain whether CORM-3 mediates its effects through a mechanism involving the endogenous generation of NO.
• L-NAME 100 ⁇ M significantly attenuated the relaxation effect elicited by each addition of CORM-3.
• CORM-3 caused approximately 37% relaxation but the presence of L-NAME in the organ bath reduced the extent of relaxation to 5%.
• the effect of L-NAME was reversed by increasing the concentration of CORM-3 (200 and 400 ⁇ M) .
• a similar effect was obtained by removing the endothelium from the vessel . As shown in Fig.
• Example 5 Effect of CORM-3 and YC-1 on mean arterial pressure.
• Lewis rats (280-350 g) were anaesthetised by intramuscular injection of 1 ml/kg Hypnorm. Specially designed femoral artery and venous catheters were then surgically implanted as previously described (5; 6) and blood pressure monitored continuously using a polygraph recorder. Rats were administered with one bolus of CORM-3 (30 ⁇ moles/kg) and after 20 min with a second bolus. CORM-3 was injected intravenously and the change in mean arterial pressure MAP recorded 20 min after each injection.
• the sGC activator (1.2 ⁇ moles/kg) was administered intravenously 5 min prior to the first injection of CORM-3.
• the effect of CORM-3 alone or in combination with YC-1 on mean arterial pressure (MAP) in vivo is summarized in Fig. 7.
• Two bolus of CORM-3 (30 ⁇ moles/kg) were injected intravenously 20 min apart from each other and the change in MAP recorded.
• the sGC activator (1.2 ⁇ moles/kg) was administered intravenously 5 min prior to the first injection of CORM-3.
• CORM-3 alone produced a rapid and significant decrease in MAP; specifically, the first injection of CORM-3 produced a decrease in MAP of 9.4 ⁇ 2.8 mmHg whereas the second bolus of CORM-3 resulted in a drop of 13.3 ⁇ 4.9 mmHg.
• the injection of YC-1 potentiated the hypotensive effects mediated by CORM-3.
• Administration of YC-1 lead to a decrease in MAP (7.0+1.6 mmHg) after 5 min; the subsequent injections of CORM-3 amplified this effect resulting in a decrease in MAP of 37.0+2.4 and 22.0 ⁇ 2.3 mmHg after the first and second injection, respectively.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Pulmonology (AREA)
• Toxicology (AREA)
• Inorganic Chemistry (AREA)
• Rheumatology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Dermatology (AREA)
• Biochemistry (AREA)
• Gynecology & Obstetrics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Transplantation (AREA)
• Orthopedic Medicine & Surgery (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9948224

Family Applications (1)

Country Status (6)

Cited By (9)

Families Citing this family (8)

Citations (1)

Family Cites Families (5)

• 2002
  • 2002-11-20 GB GB0227135A patent/GB2395431A/en not_active Withdrawn
• 2003
  • 2003-11-20 US US10/535,226 patent/US20060147548A1/en not_active Abandoned
  • 2003-11-20 EP EP03811438A patent/EP1562579A1/en not_active Withdrawn
  • 2003-11-20 WO PCT/GB2003/005061 patent/WO2004045599A1/en not_active Ceased
  • 2003-11-20 AU AU2003302013A patent/AU2003302013A1/en not_active Abandoned
  • 2003-11-20 JP JP2004552908A patent/JP2006508972A/ja active Pending

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events